Facebook
Twitter
LinkedIn
ForwardVirtual Liver Cancer Conference
The goal of this course module is to help clinicians and other service providers understand the management of Hepatocellular Carcinoma in the US population, innovations in therapies and advances in research and development.
At course completion, attendees should be able to: Increase Knowledge Understand the molecular classification of HCC Understand the multidisciplinary approach to management of HCC Competency Define the mechanisms that lead to the development of hepatocellular cancer (HCC) Performance Discuss the available evidence-based data on promising treatment options for advanced HCC Discuss the advances in research and development
Target Audience
Nurse Practitioner
Physician
Physician Assistant
Learning Objectives
At course completion, attendees should be able to:
Increase Knowledge
Understand the molecular classification of HCC.
Understand the multidisciplinary approach to management of HCC.
Competency
Define the mechanisms that lead to the development of hepatocellular cancer (HCC).
Performance
Discuss the available evidence-based data on promising treatment options for advanced HCC
Discuss the advances in research and development.
Additional Information
| Attachment | Size |
|---|---|
 2022 CLA Liver Cancer Conference Handout.pdf | 96.7 KB |
9:45 -10:00 a.m. Welcome and Overview
Dulabh K Monga, MD and Satdarshan (Paul) Monga, MD
Course Directors
Suzanna Masartis
CEO, Community Liver Alliance
10:00 a.m. How Does Liver Cancer Develop?
Satdarshan (Paul) Monga, MD
Professor and Vice Chair of Pathology
Director, Pittsburgh Liver Research Center
University of Pittsburgh and UPMC
Pittsburgh, PA
10:30 a.m. HCC Surveillance in High Risk Liver Cancer
Renumathy Dhanasekaran, MD
Assistant Professor, Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Stanford, CA
11:00 a.m. Role of Surgical Resection and
Transplantation in HCC Management
Rachel Tindall, MD, FACS
Transplant Surgeon, Hepatobiliary & Pancreas Cancer
Allegheny Health Network
Pittsburgh, PA
11:30 a.m. Concurrent Session
Role of Locoregional Therapies in HCC Management
Riad Salem, MD
Vice-Chair, Image-Guided Therapy
Chief, Interventional Radiology and Oncology
Department of Radiology
Feinberg School of Medicine
Northwestern University
Chicago, IL
12:00 p.m. BREAK/Exhibits
12:30 p.m. Medical Management of HCC
Dulabh K Monga, MD
Associate Professor of Medicine
Drexel University School of Medicine
Allegheny Health Network Cancer Institute
Pittsburgh, PA
1:00 p.m. Radiation Therapy for HCC
Paul Renz, DO
Radiation Oncology Specialist
Allegheny Health Network Cancer Institute
Pittsburgh, PA
1:30 p.m. Molecular Pathology of Hepatobiliary Tumors
Aatur Singhi, MD, PhD
Assistant Professor of Pathology
University of Pittsburgh and UPMC
Pittsburgh, PA
2:00 p.m. Advances in the Management of Biliary Tract Cancers
Rachna Shroff, MD, MS
Associate Professor of Medicine
Chief, GI Medical Oncology
University of Arizona Cancer Center
Tucson, AZ
2:30 p.m. Palliative Care of Cancer Patients
Sidra Anwar, MD
Hospice & Palliative Medicine Specialist
Allegheny Health Network
Pittsburgh, PA
3:00 p.m. Case Presentations/Q & A
Resectable/Transplantable HCC
Non-Resectable Non-Transplantable HCC and
Medical and Locoregional Options
Intrahepatic Cholangiocarcinoma
Paul Renz, DO
Dulabh Monga, MD
Riad Salem, MD
Rachna Shroff, MD
Rachel Tindall, MD
4:00 p.m. Adjournment
Course Directors:
Dulabh K. Monga, MD
Program Director
Hematology Oncology Fellowship
Assistant Professor of Medicine
Temple University School of Medicine
Allegheny Health Network
Pittsburgh, PA
Satdarshan (Paul) Singh Monga, MD
UPMC Endowed Chair for Experimental Pathology
Professor of Pathology and Medicine
Director, Pittsburgh Liver Research Center,
Chief and Vice Chair, Division of Experimental Pathology
University of Pittsburgh, School of Medicine and UPMC
Pittsburgh, PA
Faculty Disclosure:
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 5.75 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 5.75 Attendance
Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by emailing Jill Harlan at Harlanjs2@gmail.com
Please reach out to Jill Harlan at Harlanjs2@gmail.com or 4128601460 if there are additional questions.